Amivantamab联合Lazertinib治疗经治EGFR突变肺癌脑及软脑膜转移的2期研究
该2期试验评估Amivantamab联合Lazertinib在经治后出现新发或进展性中枢神经系统转移的EGFR突变肺癌患者中的疗效。脑转移组20例,软脑膜转移组21例,复合客观缓解率分别为50%和33%,中位无进展生存期分别为5.8个月和7.8个月。结论认为该联合方案在这两类患者中具有抗肿瘤活性,并证明将软脑膜转移患者纳入前瞻性临床试验的可行性。
要点
- 脑转移组复合ORR为50%,软脑膜转移组为33%。
- 脑转移组中位PFS为5.8个月,软脑膜转移组为7.8个月。
- 该联合方案在经治EGFR突变肺癌中枢神经系统转移中显示抗肿瘤活性。
核心结论
- Amivantamab联合Lazertinib在经治后出现新发或进展性脑转移或软脑膜转移的EGFR突变肺癌患者中具有抗肿瘤活性。
- 该试验证明将软脑膜转移患者纳入前瞻性临床试验是可行的。
研究设计与样本
- 2期试验(NCT04965090),评估Amivantamab联合Lazertinib,分脑转移组和经细胞学诊断的软脑膜转移组。
- 入组患者为具有致敏性EGFR激活突变或外显子20插入的肺癌患者,共治疗20例脑转移和21例软脑膜转移患者。
主要发现
- 脑转移组复合最佳ORR为50%(95%CI 27%-73%),软脑膜转移组为33%(95%CI 15%-57%)。
- 脑转移组中位PFS为5.8个月(95%CI 3.6-未达到),软脑膜转移组为7.8个月(95%CI 4.2-12.2)。
- 脑转移组中位OS为17.4个月(95%CI 15.4-未达到),软脑膜转移组为14.4个月(95%CI 8.9-未达到)。
关键数值与推荐
- 主要终点为复合最佳ORR,依据RECIST v1.1联合RANO-BM或RANO-LM评估。
- 患者中41%为EGFR del19,37%为L858R,12%为ex20ins,10%为不常见突变。
- 既往治疗中位线数为2线(范围1-7)。
临床怎么用
- 对于经治后出现新发或进展性脑转移或软脑膜转移的EGFR突变肺癌患者,可考虑Amivantamab联合Lazertinib治疗。
- 软脑膜转移患者可纳入前瞻性临床试验进行评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Despite improved central nervous system (CNS) disease control with osimertinib, 20% of patients will develop CNS progression. Amivantamab and lazertinib have demonstrated activity in patients with EGFR-mutant lung cancer. This trial evaluated amivantamab and lazertinib in patients with new or progressive CNS metastases after prior therapy (NCT04965090). METHODS: We evaluated amivantamab and lazertinib in two cohorts: patients with (1) brain metastases (BrM) or (2) leptomeningeal disease (LMD) diagnosed by cytology in patients with lung cancers with sensitizing EGFR-activating mutations or exon 20 insertions. The primary end point was composite best overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 and Response Assessment in Neuro-Oncology brain metastases or Response Assessment in Neuro-Oncology leptomeningeal metastases. Secondary end points were toxicity, systemic ORR, CNS ORR, time on treatment, progression-free survival (PFS), CNS PFS, and overall survival. RESULTS: We treated 20 patients with BrM and 21 patients with LMD. Of the patients, 41% had EGFR del19, 37% L858R, 12% ex20ins, and 10% uncommon mutations. Median lines of prior therapy were 2 (range 1-7). The ORR by a combination of Response Evaluation Criteria in Solid Tumors and Response Assessment in Neuro-Oncology brain metastases/Response Assessment in Neuro-Oncology leptomeningeal metastases was 50% (95% confidence interval [CI], 27%-73%) for patients with BrM and 33% (95% CI, 15%-57%) for patients with LMD, respectively. The median PFS was 5.8 months (95% CI, 3.6-not reached [NR]) and 7.8 months (95% CI, 4.2-12.2) for the BrM and LMD cohorts, respectively. Median overall survival was 17.4 months (15.4-NR) in the BrM cohort and 14.4 months (8.9-NR) in the LMD cohort. CONCLUSIONS: Amivantamab plus lazertinib has antitumor activity in patients with EGFR-mutant lung cancers who develop new or progressing BrM or LMD. This trial demonstrates the feasibility of including patients with LMD in prospective clinical trials.
引用
- Chen MF, Lee JJ, Choudhury NJ, et al. Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal Metastases. J Thorac Oncol. 2025. PMID: 41139066. doi:10.1016/j.jtho.2025.10.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。